| Bioactivity | α-Glucosidase-IN-15 (Compound 14B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.34 μM. α-Glucosidase-IN-15 shows antidiabetic activity[1]. |
| Target | IC50: 3.34 μM (α-glucosidase) |
| In Vivo | α-Glucosidase-IN-15 (Compound 14B) (10 and 20 mg/kg; p.o.; b.w. for 4 weeks) shows antidiabetic activity in Streptozocin (HY-13753)-induced diabetic rats[1].α-Glucosidase-IN-15 (10 and 20 mg/kg; p.o.; once) significantly decreases the serum glucose level after the administration of glucose (3 g/kg, oral) in rats[1].α-Glucosidase-IN-15 (2000mg/kg; p.o.; b.w. for 2 weeks) demonstrates no mortality in mice[1]. Animal Model: |
| Name | α-Glucosidase-IN-15 |
| Formula | C24H24N2S |
| Molar Mass | 372.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mehmood R, et al. Synthesis of Novel 2, 3-Dihydro-1, 5-Benzothiazepines as α-Glucosidase Inhibitors: In Vitro, In Vivo, Kinetic, SAR, Molecular Docking, and QSAR Studies. ACS Omega, 2022. |